Rosanna Wustrack, MD, elected President-Elect of UCSF Medical Staff


Dr. Rosanna Wustrack, above at center, an orthopaedic oncologist, will serve as President-elect of the UCSF Medical Staff, provides essential credentialing services for the UCSF Health System. (Photo:  UCSF Department of Orthoapedic Surgery)

SAN FRANCISCO (July 10, 2024) -- The UCSF Department of Orthopaedic Surgery is pleased to announce that Dr. Rosanna Wustrack has been elected as the President-Elect of the UCSF Medical Staff. This significant appointment is a testament to Dr. Wustrack's dedication and leadership within the medical community.

Effective July 1, 2024, Dr. Wustrack began her term as President-Elect, succeeding Dr. Lee Atkinson-McEvoy. She will serve in this capacity until June 30, 2026, after which she will assume the role of President of the UCSF Medical Staff from July 1, 2026, to June 30, 2028. In her role as President-Elect, Dr. Wustrack will also chair the Credentials Committee.

About UCSF Office of Medical Affairs and Governance

The UCSF Office of Medical Affairs and Governance, which Dr. Wustrack will be closely involved with, provides essential credentialing services for the UCSF Health System. This office primarily serves UCSF faculty from the School of Medicine and the School of Dentistry, as well as affiliated community partner groups within the clinically integrated physician network. They are responsible for enrolling providers with contracted health plans and play a crucial role in the health system's billing and revenue operations. Additionally, the office offers expert guidance and consultation to UCSF leadership on medical staff governance and physician peer review.

The Office of Medical Affairs and Governance oversees nearly 4,000 providers at UCSF Medical Center at Parnassus Heights, UCSF Benioff Children's Hospital at Mission Bay, UCSF Bakar Cancer Hospital, UCSF Moore Women's Hospital, UCSF Langley Porter Hospital and Clinics, UCSF Faculty Practice, UCSF Clinically-Integrated Network, and UCSF Benioff Children's Physician Foundation.

Their integrated operations, including Payer Enrollment Affairs (health plan enrollment, revalidations, and denial work queue management), are embedded with credentialing, privileging, and medical staff regulatory governance. In coordination with the UCSF Office of Legal Affairs, the Office of Medical Affairs and Governance handles all medical staff peer review investigations. They are instrumental in the development of the UCSF clinically-integrated physician network and continue to partner with UCSF's Business Strategy, Affiliation Integration, and Population Health and Accountable Care.

The Office of Medical Affairs and Governance reports to the UCSF Health System's Executive Vice President of Physician Services and the elected UCSF Medical Staff President. Its responsibilities and functions are reported monthly to the UCSF governing body chaired by the Chancellor.

About Rosanna Wustrack, MD

Dr. Rosanna Wustrack is an orthopedic surgeon who specializes in the surgical diagnosis and treatment of musculoskeletal tumors and fragility fractures. She is Chief of the Orthopaedic Oncology Service at UCSF. In the 2023 academic year, she served as Acting Chair of the UCSF Department of Orthopaedic Surgery.

Her research focuses on immunotherapy for sarcomas, functional outcomes in cancer patients, osseointegration, and optimizing treatment for metastatic disease. She also has interests in global health and osteoporosis in cancer survivors.

Dr. Wustrack received an undergraduate degree from Yale University and a medical degree from Washington University School of Medicine in St. Louis. She completed an internship and residency in orthopedic surgery at UCSF, followed by fellowship training in musculoskeletal oncology at Memorial Sloan Kettering Cancer Center in New York.

Additionally, Dr. Wustrack is a member of the UCSF Sarcoma Center, a multidisciplinary team of sarcoma specialists who provide patients with the most precise diagnostic tools, novel surgical and reconstructive techniques, and promising new therapies.